Amalgamated Bank Has $5.46 Million Position in Envista Holdings Co. (NYSE:NVST)

Amalgamated Bank cut its position in shares of Envista Holdings Co. (NYSE:NVSTGet Rating) by 3.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 112,014 shares of the company’s stock after selling 3,568 shares during the period. Amalgamated Bank’s holdings in Envista were worth $5,456,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Massachusetts Financial Services Co. MA increased its position in Envista by 48.1% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 7,877,292 shares of the company’s stock worth $383,703,000 after purchasing an additional 2,557,951 shares in the last quarter. Jennison Associates LLC increased its position in shares of Envista by 191.3% during the first quarter. Jennison Associates LLC now owns 1,823,357 shares of the company’s stock worth $88,816,000 after buying an additional 1,197,432 shares during the period. Principal Financial Group Inc. increased its position in shares of Envista by 140.5% during the first quarter. Principal Financial Group Inc. now owns 1,318,947 shares of the company’s stock worth $64,247,000 after buying an additional 770,581 shares during the period. Leeward Investments LLC MA acquired a new stake in shares of Envista during the first quarter worth $37,385,000. Finally, Alyeska Investment Group L.P. bought a new position in Envista during the first quarter worth $36,982,000.

Envista Price Performance

NVST opened at $34.83 on Tuesday. The company has a market capitalization of $5.69 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 1.36 and a beta of 1.54. The company has a quick ratio of 0.88, a current ratio of 1.11 and a debt-to-equity ratio of 0.22. The firm has a 50-day moving average price of $38.49 and a 200-day moving average price of $41.48. Envista Holdings Co. has a twelve month low of $33.84 and a twelve month high of $52.03.

Envista (NYSE:NVSTGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.02. Envista had a net margin of 11.86% and a return on equity of 8.26%. The company had revenue of $645.80 million during the quarter, compared to analyst estimates of $657.55 million. Equities analysts expect that Envista Holdings Co. will post 1.98 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Robert W. Baird lowered shares of Envista from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $54.00 to $46.00 in a research note on Tuesday, June 14th. Evercore ISI dropped their price objective on shares of Envista to $44.00 in a research note on Tuesday, August 9th. TheStreet lowered shares of Envista from a “b” rating to a “c+” rating in a research note on Friday, June 17th. Stifel Nicolaus dropped their price target on shares of Envista from $55.00 to $50.00 in a research report on Friday, June 17th. Finally, The Goldman Sachs Group dropped their price target on shares of Envista from $58.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.86.

Envista Profile

(Get Rating)

Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands.

Featured Articles

Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Co. (NYSE:NVSTGet Rating).

Institutional Ownership by Quarter for Envista (NYSE:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.